

Table S3. Multivariate analysis: independent risk factors and protective factors for damage accrual over the follow-up. The cumulative time spent in remission has been used as independent variable.

Number of patients with different duration of remission: 1 cumulative year: 25 (8.5%); 2 cumulative years: 23 (7.8%); 3 cumulative years: 30 (10.2%); 4 cumulative years: 42 (14.4);  $\geq 5$  cumulative years: 138 (47.0%). Unremitted disease: 35 patients (11.9%).

	B	p value	OR	95% CI
<b><math>\geq 5</math> cumulative year remission</b>	-2.575	<b>&lt;0.001</b>	<b>0.076</b>	<b>0.023 - 0.250</b>
<b>4 cumulative year remission</b>	-1.652	<b>0.01</b>	<b>0.192</b>	<b>0.052 - 0.708</b>
<b>3 cumulative year remission</b>	-1.695	<b>0.015</b>	<b>0.184</b>	<b>0.047 - 0.716</b>
2 cumulative year remission	-0.990	0.222	0.372	0.076 - 1.819
1 cumulative year remission	-0.292	0.707	0.747	0.163 - 3.421
<b>Disease duration</b>	0.053	<b>0.008</b>	<b>1.055</b>	<b>1.014 - 1.097</b>
<b>Antiphospholipid antibody syndrome</b>	1.225	<b>0.007</b>	<b>3.406</b>	<b>1.401 - 8.281</b>
<b>Cumulative average PDN dose <math>\geq 180</math> mg/month</b>	0.769	<b>0.035</b>	<b>2.158</b>	<b>1.057 - 4.407</b>
<b>Vasculitis ever</b>	1.249	<b>0.020</b>	<b>3.488</b>	<b>1.215 - 10.012</b>
Cyclophosphamide	0.631	0.069	1.889	0.953 - 3.747
SDI at baseline	0.065	0.665	1.197	0.904 - 1.584
<b>Age</b>	0.038	<b>0.002</b>	<b>1.039</b>	<b>1.014 - 1.097</b>
Constant	-1.314	0.103	0.269	

PDN, prednisone-equivalent

SDI, SLICC/ACR damage index